Gerresheimer invests some $94 million in US expansion

Gerresheimer AG, a provider of health and beauty care solutions and drug delivery systems for the pharmaceutical, biotech and cosmetics industries, announced investments to rapidly expand its manufacturing, supply and logistics for glass vials in the United States

The project will be supported by the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) of the United States Department of Health and Human Services (HHS) with support departmental contractor. of Defense (DOD).

It will expand Gerresheimer’s capability with new vial forming lines, including dimensional inspection, annealing, cosmetic inspection and packaging. BARDA has agreed to provide up to approximately $66 million for this project.

Gerresheimer will expand its annual production capacity in Morganton, NC with Type 1 interchangeable vials (borosilicate and/or aluminosilicate glass) and Gx Elite glass vial capacity.

BARDA’s funding, with contract support from the DOD’s Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) and the Army Contracting Command (ACC), will enhance U.S. capabilities respond to current and future public demands. health emergencies.

The vials can be used in vaccination campaigns against infectious diseases, such as COVID-19 and others.

As part of the project, the existing facility in North Carolina will be expanded with the installation of new vial forming lines and a new warehouse. New offices will also be part of the expansion plan.

Comments are closed.